{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:19:44Z","timestamp":1792091984749,"version":"4.4.0"},"reference-count":71,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Ceftobiprole combines an excellent spectrum for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) pathogens, with a low\/medium MDR risk, and the \u03b2-lactams\u2019 safety in frail patients admitted to the hospital in internal medicine wards which may be at high risk of adverse events by anti-MRSA coverage as oxazolidinones or glycopeptides. We aimed to report the available evidence regarding ceftobiprole use in pneumonia and invasive bacterial infections, shedding light on ceftobiprole stewardship. The clinical application and real-life experiences of using ceftobiprole for bloodstream infections, including infective endocarditis, are limited but nevertheless promising. In addition, extended-spectrum ceftobiprole activity, including Enterococcus faecalis, Enterobacteriaceae, and Pseudomonas aeruginosa, has theoretical advantages for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as catheter-related bacteremia. In the future, the desirable approach to sepsis and severe infections will be administered to patients according to their clinical situation, the intrinsic host characteristics, the susceptibility profile, and local epidemiology, while the \u201cuniversal antibiotic strategy\u201d will no longer be adequate.<\/jats:p>","DOI":"10.3390\/antibiotics10020170","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T23:43:16Z","timestamp":1612914196000},"page":"170","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Ceftobiprole Perspective: Current and Potential Future Indications"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-9519","authenticated-orcid":false,"given":"Tommaso","family":"Lupia","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Cardinal Massaia Hospital, 14100 Asti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-2885","authenticated-orcid":false,"given":"Carlo","family":"Pallotto","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Central District, Tuscany Health Care, Bagno a Ripoli, 500012 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10124 Turin, Italy"},{"name":"Infectious Diseases, Tufts University School of Medicine, Boston, MA 02109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Boglione","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-0130","authenticated-orcid":false,"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Cardinal Massaia Hospital, 14100 Asti, Italy"},{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril vs. ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, doubleblind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","article-title":"Ceftobiprole: Drug evaluation and place in therapy","volume":"17","author":"Giacobbe","year":"2019","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: A review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.00257-08","article-title":"Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against com-munity-associated and hospital-associated methicillin-resistant Staphylococcus aureus","volume":"52","author":"Leonard","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijantimicag.2009.02.013","article-title":"Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials","volume":"34","author":"Davies","year":"2009","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/mdr.2014.0307","article-title":"Genotypic characterization of methicillin-resistant Staphylococcus aureus recovered at baseline from phase 3 pneumonia clinical trials for ceftobiprole","volume":"22","author":"Mendes","year":"2016","journal-title":"Microb. Drug Resist."},{"key":"ref_10","first-page":"17","article-title":"Ceftobiprole for the treatment of pneumonia","volume":"32","author":"Torres","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_11","first-page":"4565","article-title":"Ceftobiprole for the treatment of pneumonia: A European perspective","volume":"9","author":"Liapikou","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Scheeren, T.W.L., Welte, T., Saulay, M., Engelhardt, M., Santerre-Henriksen, A., and Hamed, K. (2019). Early improvement in severely ill patients with pneumonia treated with ceftobiprole: A retrospective analysis of two major trials. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3820-y"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospitalacquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European respiratory society (ERS), European society of intensive care medicine (ESICM), European society of clinical microbiology and infectious diseases (ESCMID) and asociaci\u00f3n Latinoamericana del t\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/QCO.0000000000000598","article-title":"Carbapenem sparing strategy: Carbapenemase, treatment, and stewardship","volume":"32","author":"Corcione","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00079-17","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extend-ed-spectrumbeta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae","volume":"31","author":"Machuca","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s40262-016-0418-z","article-title":"Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations","volume":"55","author":"Torres","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1128\/AAC.00144-09","article-title":"Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole","volume":"53","author":"Rodvold","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yan, Y., Shin, W.I., Pang, Y.X., Meng, Y., Lai, J., You, C., Zhao, H., Lester, E., Wu, T., and Pang, C.H. (2020). The first 75 days of Novel Coronavirus (SARS-CoV-2) outbreak: Recent advances, prevention, and treatment. Int. J. Environ. Res. Publ. Health, 17.","DOI":"10.3390\/ijerph17072323"},{"key":"ref_20","unstructured":"(2021, January 18). COVID-19 Map\u2014Johns Hopkins Coronavirus Resource Center. Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_21","first-page":"2459","article-title":"Bacterial and fungal co-infection in in-dividuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing","volume":"71","author":"Rawson","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"198005","DOI":"10.1016\/j.virusres.2020.198005","article-title":"Co-infection with respiratory pathogens among COVID-2019 cases","volume":"285","author":"Zhu","year":"2020","journal-title":"Virus Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13613-020-00736-x","article-title":"Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU","volume":"10","author":"Contou","year":"2020","journal-title":"Ann. Inten. Care."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"COVID-19 Researchers Group. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study","volume":"27","author":"Sanjuan","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_25","first-page":"7","article-title":"Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome Coronavirus 2-positive patients hospitalized in intensive care units using conven-tional culture and biofire, filmarray pneumonia panel plus assay","volume":"22","author":"Kolenda","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2666-5247(20)30036-7","article-title":"Low rate of bacterial co-infection in patients with COVID-19","volume":"1","author":"Adler","year":"2020","journal-title":"Lancet Microbe."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.cmi.2020.06.025","article-title":"Bacterial and fungal coinfection among hospitalized patients with COVID-19: A retrospective cohort study in a UK secondary-care setting. The official publication of the European society of clinical microbiology and infectious diseases","volume":"26","author":"Hughes","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.21037\/jtd-20-417","article-title":"New cephalosporins for the treatment of pneumonia in internal medicine wards","volume":"12","author":"Lupia","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Overcash, J.S., Kim, C., Keech, R., Gumenchuk, I., Ninov, B., Gonzalez-Rojas, Y., Waters, M., Simeonov, S., Engelhardt, M., and Saulay, M. (2020). Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a phase 3, randomized, double-blind trial (TARGET). An official publication of the infectious diseases society of America. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciaa974"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Infectious diseases society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus in-fections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14656566.2018.1442826","article-title":"Current and future treatment options for community-associated MRSA infection","volume":"19","author":"Khan","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.pop.2013.06.002","article-title":"Methicillin-resistant Staphylococcus aureus infections","volume":"40","author":"Taylor","year":"2013","journal-title":"Prim. Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MJT.0b013e31821109ec","article-title":"Alternative agents to vancomycin for the treatment of methicillin-resistant S. aureus infections","volume":"20","author":"Culos","year":"2013","journal-title":"Am. J. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1469-0691.2010.03135.x","article-title":"European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: Current clinical opinion and practice","volume":"16","author":"Dryden","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC >1 mg\/L: A multicenter evaluation","volume":"38","author":"Moise","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/21548331.2019.1676540","article-title":"Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States veterans health care system","volume":"47","author":"Mootz","year":"2019","journal-title":"Hosp. Pract."},{"key":"ref_38","first-page":"2049936118808655","article-title":"Efficacy and safety of ceftaroline: Systematic review and meta-analysis","volume":"6","author":"Rosanova","year":"2018","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of be-ta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schweizer, M.L., Furuno, J.P., Harris, A.D., Johnson, J.K., Shardell, M.D., McGregor, J.C., Thom, K.A., Cosgrove, S.E., Sakoulas, G., and Perencevich, E.N. (2011). Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect. Dis., 11.","DOI":"10.1186\/1471-2334-11-279"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","article-title":"Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia","volume":"15","author":"Wong","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1093\/ofid\/ofx163.901","article-title":"Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the US (2016)","volume":"4","author":"Flamm","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_43","unstructured":"Pfaller, M.A., Mendes, R.E., Sader, H.S., Streit, J., Smart, J.I., Hamed, K.A., Duncan, L.R., and Flamm, R.K. (2018, January 7\u201311). Antimicrobial activity of ceftobiprole when tested against Gram-positive cocci causing serious infections (2016\u20132017): Endocarditis, diabetic foot, and bone\/joint infections. Proceedings of the ASM Microbe, Atlanta, GA, USA."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2017.12.020","article-title":"Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_45","first-page":"24","article-title":"Ceftobripole: Experience in staphylococcal bacteremia","volume":"32","author":"Soriano","year":"2019","journal-title":"Rev EspQuimioter."},{"key":"ref_46","unstructured":"Rello, J., Rahav Scheeren, T., Saulay, M., Engelhardt, M., and Welte, T. (2016). Pooled analysis of clinical cure and mortality with ceftobiprole medocaril versus comparators in staphylococcal bacteremia in complicated skin infections, community- and hospital-acquired pneumonia. ECCMID, O-318."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jgar.2020.03.010","article-title":"Real life experience with ceftobiprole in a tertiary-care hospital","volume":"22","author":"Andini","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/fmb-2019-0332","article-title":"Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: A novel protocol for a double-blind, Phase III trial","volume":"15","author":"Hamed","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1093\/eurheartj\/ehz620","article-title":"EURO-ENDO Investigators. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: A pro-spective cohort study","volume":"40","author":"Habib","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_50","first-page":"124","article-title":"Trends in infective endocarditis in a medi-um-sized University Hospital in Italy: Analysis of 232 cases","volume":"22","author":"Pallotto","year":"2014","journal-title":"Infez. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e02208-7","DOI":"10.1128\/AAC.02208-17","article-title":"Risk factors and outcomes of endocarditis due to non-HACEK Gram-negative bacilli: Data from the prospective multicenter Italian endocarditis study cohort","volume":"62","author":"Falcone","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.00886-09","article-title":"Ceftobiprole is superior to vancomycin, daptomycin and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant S. aureus","volume":"54","author":"Tattevin","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.06057-11","article-title":"Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate S. aureus","volume":"56","author":"Fernandez","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00402-11","article-title":"In vivo synergism of ceftobiprole and vanco-mycin against experimental endocarditis due to vancomycin-intermediate S. aureus","volume":"55","author":"Entenza","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","unstructured":"Esposito, F., Efthymiou, A., Van Delden, C., and Erard, V. (2018, January 13\u201314). Ceftobiprole as an ultimate successful therapy for MRSE prosthetic endo-vascular infection judged to be medically untreatable in a profound immunocompromised patient: A case report. Proceedings of the Joint Annual Meeting 2018, Swiss Societies for Infectious Diseases (SSI), Hospital Hygiene (SSHH), Tropical Medicine and Parasitology (SSTMP) and Tropical and Travel Medicine (SSTTM), Interlaken, Switzerland. Poster P88."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diagmicrobio.2007.02.010","article-title":"In vitro activity of ceftobiprole, daptomycin, linezolid and vancomycin against methi-cillin-resistant staphylococci associated with endocarditis and bone and joint infection","volume":"58","author":"Rouse","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"115153","DOI":"10.1016\/j.diagmicrobio.2020.115153","article-title":"In vitro activity of ceftaroline and ceftobiprole against clinical isolates of Gram-positive bacteria from infective endocarditis: Are these drugs potential options for the initial management of this disease?","volume":"98","author":"Telenti","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1093\/jac\/dkz388","article-title":"In vitro bactericidal activity of amoxicillin combined with different cephalosporins against endocarditis-associated Enterococcus faecalis clinical isolates","volume":"74","author":"Guillotel","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1128\/AAC.46.1.171-177.2002","article-title":"BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis","volume":"46","author":"Entenza","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2147\/IDR.S254395","article-title":"Ceftobiprole for treatment of MRSA blood stream infection: A case series","volume":"13","author":"Mahmoud","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.07.020","article-title":"Ceftobiprole for the treatment of infecive endocarditis: A case series","volume":"20","author":"Tascini","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ijantimicag.2016.04.006","article-title":"Methicillin-resistant Staphylococcus aureus endocarditis: First report of daptomycin plus ceftobiprole combination as salvage therapy","volume":"47","author":"Oltolini","year":"2016","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2018.07.015","article-title":"Bactericidal activity of ceftobiprole combined with different antibiotics against selected gram positive isolates","volume":"93","author":"Campanile","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/jac\/dku236","article-title":"Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes","volume":"69","author":"Barber","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1128\/AAC.01537-10","article-title":"Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (\u03b2-lactamase positive and \u03b2-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model","volume":"56","author":"Stucki","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","first-page":"1","article-title":"Antibiotic treatment in patients with sepsis: A narrative review","volume":"20","author":"Ferrer","year":"2020","journal-title":"Hosp. Pract."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0034-1398742","article-title":"Optimizing antimicrobial therapy of sepsis and septic shock: Focus on antibiotic combination therapy","volume":"36","author":"Kumar","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intens. Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1001\/jama.2012.5833","article-title":"Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: A randomized trial","volume":"307","author":"Brunkhorst","year":"2012","journal-title":"Jama"},{"key":"ref_70","first-page":"Cd003344","article-title":"Beta lactam antibiotic monotherapy versus beta lac-tam-aminoglycoside antibiotic combination therapy for sepsis","volume":"7","author":"Paul","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/cid\/cix186","article-title":"Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: A prospective observational cohort study","volume":"64","author":"Ong","year":"2017","journal-title":"Clin. Infect Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/2\/170\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:21:33Z","timestamp":1760160093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/2\/170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":71,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["antibiotics10020170"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10020170","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]}}}